Search results for "Autoimmune"

showing 10 items of 648 documents

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic …

2007

SummaryTreatment of relapsed or refractory autoimmune mediated haemolytic syndromes, such as autoimmune haemolytic anaemia (AIHA) and thrombotic thrombocytopenic purpura (TTP), represents a therapeutic challenge. Here we report on our experience with the monoclonal anti-CD20 antibody rituximab (R) compared to standard treatment in these diseases. Patients with non-familialTTP orAIHA and no underlying malignancy were included in our analysis. Safety and efficacy of R-treatment were compared to results obtained in standard treatment approaches. Altogether, 27 patients were analyzed, comprising 15 patients withTTP and 12 patients with AIHA. The patients’ average age at the time of diagnosis wa…

AdultMalemedicine.medical_specialtyTime FactorsThrombotic thrombocytopenic purpuraSalvage therapyGastroenterologyDisease-Free SurvivalAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRecurrenceMedian follow-upGermanyhemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProgression-free survivalAgedRetrospective StudiesSalvage TherapyPurpura Thrombocytopenic Idiopathicbusiness.industryStandard treatmentAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeDrug Therapy CombinationFemaleRituximabAnemia Hemolytic AutoimmuneRituximabbusinessFollow-Up Studiesmedicine.drugThrombosis and Haemostasis
researchProduct

Islet autoantibodies in Latvian subjects with non-insulin-dependent diabetes mellitus: slow-onset type 1 diabetes or polyendocrine autoimmunity?

2006

In Latvia diabetes mellitus is diagnosed using the WHO's clinical criteria; assays for the detection of autoantibodies are not available, and hence slowly progressive autoimmune diabetes is likely to be missed. Autoantibodies against glutamic acid decarboxylase (GAD65) and protein tyrosine phosphatase (IA-2) among patients with clinically diagnosed NIDDM identify group of patients with slow-onset type 1 diabetes or LADA. The aim of this study was to estimate the risk of polyendocrine autoimmunity among clinically diagnosed NIDDM patients from Latvia. One hundred NIDDM patients and 100 healthy controls were tested for GAD65 and IA-2 autoantibodies as well as 21-hydroxylase (21-OH) and tissue…

AdultMalemedicine.medical_specialtyendocrine system diseasesAdolescentTissue transglutaminasemedicine.medical_treatmentOverweightmedicine.disease_causeAutoantigensGeneral Biochemistry Genetics and Molecular BiologyAutoimmunityDiagnosis DifferentialHistory and Philosophy of ScienceInternal medicineDiabetes mellitusmedicineHumansReceptor-Like Protein Tyrosine Phosphatases Class 8ChildPolyendocrinopathies AutoimmuneAutoantibodiesProtein Tyrosine Phosphatase Non-Receptor Type 1Type 1 diabetesbiologybusiness.industryGlutamate DecarboxylaseGeneral NeuroscienceInsulinAutoantibodynutritional and metabolic diseasesMembrane Proteinsmedicine.diseaseLatviaIsoenzymesEndocrinologyDiabetes Mellitus Type 1Child Preschoolbiology.proteinFemalemedicine.symptomProtein Tyrosine PhosphatasesbusinessBody mass indexBiomarkersAnnals of the New York Academy of Sciences
researchProduct

Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study

2019

Background: Graves' disease is one of the most common autoimmune conditions, but treatment remains imperfect. This study explores the first-in-human use of antigen-specific immunotherapy with a combination of two thyrotropin receptor (TSHR) peptides (termed ATX-GD-59) in Graves' hyperthyroidism. Methods: Twelve participants (11 female) with previously untreated mild to moderate Graves' hyperthyroidism were enrolled in a Phase I open label trial to receive 10 doses of ATX-GD-59 administered intradermally over an 18-week period. Adverse events, tolerability, changes in serum free thyroid hormones, and TSHR autoantibodies were measured. Results: Ten subjects received all 10 doses of ATX-GD-59,…

AdultMalemedicine.medical_specialtyendocrine systemendocrine system diseasesInjections Intradermalthyroid stimulating hormone receptorEndocrinology Diabetes and Metabolismmedicine.medical_treatmentGraves' diseasedesensitization030209 endocrinology & metabolismDiseaseImmunology Autoimmunity and Graves’ OphthalmopathyimmunomodulationThyrotropin receptor03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinemedicineHumansAdverse effectDesensitization (medicine)business.industryAutoantibodypeptide immunotherapyReceptors ThyrotropinImmunotherapyMiddle Agedmedicine.diseaseGraves' diseaseGraves Disease3. Good healthInjection Site ReactionThyroxineEndocrinologyTreatment OutcomeTolerabilityDesensitization Immunologic030220 oncology & carcinogenesisTriiodothyronineFemaleautoimmune thyroid diseasebusinessPeptidesImmunoglobulins Thyroid-StimulatingThyroid
researchProduct

Ciamexone in endocrine orbitopathy. A randomized double-blind, placebo-controlled study.

1990

Abstract The influence of ciamexone on the activity and course of endocrine orbitopathy was investigated. Fifty-one patients with active orbitopathy classes II-VI were allocated randomly to two groups: over a period of six months, 26 patients received 300 mg/day ciamexone and 25 patients received placebo tablets. In both groups, prednisolone was administered in addition in the first four weeks. Ophthalmological investigations and clinical tests as well as orbit sonography were carried out before as well as one, three and six months after the beginning of therapy. Before and after treatment, computer tomography of the orbit was performed. Symptoms and signs did not show any significant impro…

AdultMalemedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEye diseasePrednisoloneAziridinesPlacebo-controlled studyVisual AcuityPlaceboRandom AllocationEndocrinologyAdjuvants ImmunologicDouble-Blind MethodInternal medicineOrbital DiseasesMedicineHumansExophthalmusIntraocular PressureAgedChemotherapybiologybusiness.industryThyroiditis AutoimmuneEndocrine orbitopathyGeneral MedicineMiddle Agedbiology.organism_classificationmedicine.diseaseEndocrinologyPrednisoloneCorticosteroidFemalebusinessmedicine.drugActa endocrinologica
researchProduct

Immunologic effects of rituximab on the human spleen in immune thrombocytopenia

2011

Abstract Immune thrombocytopenia (ITP) is an autoimmune disease with a complex pathogenesis. As in many B cell–related autoimmune diseases, rituximab (RTX) has been shown to increase platelet counts in some ITP patients. From an immunologic standpoint, the mode of action of RTX and the reasons underlying its limited efficacy have yet to be elucidated. Because splenectomy is a cornerstone treatment of ITP, the immune effect of RTX on this major secondary lymphoid organ was investigated in 18 spleens removed from ITP patients who were treated or not with RTX. Spleens from ITP individuals had follicular hyperplasia consistent with secondary follicles. RTX therapy resulted in complete B-cell de…

AdultMalemedicine.medical_treatmentImmunologySplenectomySpleenT-Lymphocytes RegulatoryBiochemistryAntibodies Monoclonal Murine-DerivedImmune systemimmune system diseaseshemic and lymphatic diseasesHumansImmunologic FactorsMedicineImmunobiologyAgedAutoimmune diseaseB-LymphocytesPurpura Thrombocytopenic Idiopathicbiologybusiness.industryCell BiologyHematologyMiddle AgedTh1 Cellsmedicine.diseaseLymphatic systemmedicine.anatomical_structureImmunologyMonoclonalbiology.proteinFemaleRituximabAntibodyRituximabbusinessSpleenmedicine.drugBlood
researchProduct

Analysis of the in vitro cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis.

1993

SUMMARY The pathogenic mechanisms underlying the development of autoimmune hepatitis (AIH) are still unclear. Since AIH is associated with the presence of various autoantibodics and certain HLA subtypes, it is likely that T and B cells play a major role in this disease. In this study we have determined the functional capacities of in vivo preactivated liver-infiltrating T cells (LTC) from patients with AIH. As controls we used LTC from patients with non-autoimmune hepatitis (non-AIH). Our results show that preactivated LTC from patients with AIH predominantly (190/255 clones) reside in the CD4+ population, whereas LTC in non-AIH are dominated by the CD8+ phenotype (148/254 clones). In view …

AdultMalemedicine.medical_treatmentT cellCD8 AntigensT-LymphocytesImmunologyPopulationAutoimmune hepatitisHuman leukocyte antigenBiologyAutoimmune DiseasesHepatitisInterferon-gammaImmune systemimmune system diseasesmedicineImmunology and AllergyHumanseducationeducation.field_of_studyTumor Necrosis Factor-alphaInterleukinsMiddle Agedmedicine.diseasedigestive system diseasesClone CellsCytokinemedicine.anatomical_structureLiverImmunologyCD4 AntigensCytokinesCytokine secretionFemaleCD8Research ArticleClinical and experimental immunology
researchProduct

Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 case…

2016

Macrophage activation syndrome (MAS) is a rare, life-threatening disease in which early diagnosis and aggressive therapeutic strategy may improve the outcome. Due to its rarity, epidemiologic data are still lacking. Hyperferritinemia is frequently associated with MAS and might modulate the cytokine storm, which is involved in the development of multiple organ failure. In this paper, we investigated clinical data, treatments, and outcome of a homogeneous cohort of 41 adult MAS patients, complicating autoimmune rheumatic diseases. MAS-related death occurred in 17 patients (42.5%) during the follow-up, and older age and increased serum ferritin levels, at the time of diagnosis, were significan…

AdultMalemusculoskeletal diseases0301 basic medicinemedicine.medical_specialtyImmunologyAdult onset Still's disease; Hyperferritinemic syndrome; Macrophage activation syndrome; Adult; Ambulatory Care Facilities; Autoimmune Diseases; Female; Humans; Immunosuppressive Agents; Macrophage Activation Syndrome; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Immunology and Allergy; ImmunologyDiseaseAmbulatory Care FacilitiesAutoimmune Diseases03 medical and health sciences0302 clinical medicineAdult onset Still's diseaseInternal medicineHumansImmunology and AllergyMedicineRetrospective Studies030203 arthritis & rheumatologyAutoimmune diseaseAdult patientsbusiness.industryMortality ratefungiRetrospective cohort studyMiddle AgedPrognosisHyperferritinemic syndromemedicine.diseasebody regionsSettore MED/16 - ReumatologiaTreatment Outcome030104 developmental biologyMacrophage activation syndromeMacrophage activation syndromeCohortImmunologyFemalelipids (amino acids peptides and proteins)businessCytokine stormImmunosuppressive Agentshormones hormone substitutes and hormone antagonistsAutoimmunity Reviews
researchProduct

Soluble Interleukin-2 Receptor Secretion Defectin Vitroin HLA-B8, DR3 Positive Subjects

1990

Several studies have shown that HLA-B8,DR3 positive subjects may display T cell dysfunctions. Recently, a soluble form of the receptor for IL-2 (sIL-2R) has been demonstrated in human sera and in vitro-stimulated culture supernatant from human T lymphocytes. In the present paper we report sIL-2R serum levels and sIL-2R production from peripheral blood mononuclear cells in HLA-B8,DR3 positive subjects. We found that HLA-B8,DR3 positive subjects have the highest values of serum sIL-2R, but comparing the values of these subjects with those of negative ones no significant difference was observed. As regards the in vitro production of sIL-2R, no difference exists for unstimulated cultures, where…

AdultMalemusculoskeletal diseasesInterleukin 2medicine.medical_specialtyAdolescentT cellImmunologyStimulationHuman leukocyte antigenBiologyLymphocyte Activationmedicine.disease_causePeripheral blood mononuclear cellAutoimmune DiseasesHLA-B8 AntigenAutoimmunityHLA-DR3 AntigenT-Lymphocyte Subsetsimmune system diseasesInternal medicinemedicineHumansImmunology and AllergyGenetic Predisposition to DiseaseReceptorSicilyCells CulturedImmunologic Deficiency SyndromesReceptors Interleukin-2Middle AgedIn vitroDiabetes Mellitus Type 1medicine.anatomical_structureEndocrinologySolubilityImmunologyLeukocytes MononuclearFemaleDisease SusceptibilityProtein Processing Post-Translationalmedicine.drugAutoimmunity
researchProduct

Autoimmune polyglandular syndrome type 2 shows the same HLA class II pattern as type 1 diabetes†

2011

Autoimmune polyglandular syndrome (APS) type 2 is defined by the manifestation of at least two autoimmune endocrine diseases. Only few data exist on genetic associations of APS type 2. In this controlled study, 98 patients with APS type 2, 96 patients with type 1 diabetes (T1D), and 92 patients with autoimmune thyroid disease, both as a single autoimmune endocrinopathy, were tested for association with alleles of the human leukocyte antigen (HLA) class II loci DRB1, DQA1, and DQB1. Patients with APS type 2 had significantly more often the alleles DRB1*03 (P(c) < 0.0001), DRB1*04 (P(c) < 0.000005), DQA1*03 (P(c) < 0.0001), and DQB1*02 (P(c) < 0.05), when compared with controls. Less frequent…

AdultMalemusculoskeletal diseasesendocrine system diseasesImmunologyHuman leukocyte antigenDiseaseBiochemistryGene Frequencyimmune system diseasesDiabetes mellitusGeneticsmedicineHumansImmunology and AllergyEndocrine systemAllelePolyendocrinopathies Autoimmuneskin and connective tissue diseasesAllelesHLA-D AntigensType 1 diabetesbusiness.industryHaplotypenutritional and metabolic diseasesGeneral MedicineMiddle Agedmedicine.diseaseDiabetes Mellitus Type 1ImmunologyAutoimmune Polyglandular Syndrome Type 2FemalebusinessTissue Antigens
researchProduct

Increased seroprevalence of parvovirus B 19 IgG in complex regional pain syndrome is not associated with antiendothelial autoimmunity

2005

The etiology of complex regional pain syndrome (CRPS) is unclear yet. Recently autoantibodies and antecedent viral infections have been discussed to be involved in the pathogenesis of CRPS. We investigated sera from 39 CRPS patients and healthy controls for parvovirus B19 IgG and the occurrence of antiendothelial autoantibodies (AECA). CRPS patients showed a higher seroprevalence of parvovirus B19 IgG than controls (p < 0.01). All CRPS 2 patients were positive. 10.2% of the CRPS patients and 10.0% of the controls had AECA (n.s.) and AECA were not associated with parvovirus B19 seropositivity. Our findings suggest the involvement of parvovirus B19, but not autoantibody-mediated endothelial c…

AdultMalevirusesEnzyme-Linked Immunosorbent AssayAntibodies Viralmedicine.disease_causeAutoimmune DiseasesAutoimmunityParvoviridae InfectionsPathogenesisSeroepidemiologic StudiesParvovirus B19 HumanmedicineHumansSeroprevalenceEndotheliumAgedAutoantibodiesbiologybusiness.industryParvovirusAutoantibodyvirus diseasesMiddle Agedbiology.organism_classificationmedicine.diseaseAnesthesiology and Pain MedicineComplex regional pain syndromeImmunoglobulin GImmunologybiology.proteinEtiologyFemaleAntibodybusinessComplex Regional Pain SyndromesEuropean Journal of Pain
researchProduct